Autoimmune Market Forecast to 2014

Drive blockbuster revenue with autoimmune breakthroughs

The autoimmune market is proving that the era of the blockbuster is not dead.

Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.

Whether you’re exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don’t miss out!

From sales projections to clinical trial data to analysts’ insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn’s disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers.

Delve into the data to:

* Learn how brands and drug classes have fared: where they’ve succeeded - and failed
* Show solid, objective evidence for your decision-making
* Keep track of the competition
* Get the latest on clinical trials
* Uncover potential business development opportunities

Please feel free to request free sample pages, or browse the table of contents from the tab above...

Chapter 1: Autoimmune Indication Snapshots

This section provides historical context, possible causes, epidemiological data, treatment information and new developments for each of the following major autoimmune indications:

* Rheumatoid arthritis
* Psoriasis and psoriatic arthritis
* Ulcerative colitis
* Crohn’s disease
* Systemic lupus erythematosus and lupus nephritis
* Multiple sclerosis


Chapters 2 and 3: Brand profiles for Biologic and Small Molecule Therapies

Organized by class, brand profiles include the following points:

* Drug’s current and projected competitive strength
* Sales projection charts through 2014
* Materiality charts
* Clinical trial information
* Patent/market exclusivity tables


Classes covered in the report:

* TNF inhibitors
* B-cell inhibitors
* Interferon betas
* Interleukin inhibitors
* Immunomodulators
* NSAIDs
* 5-ASAs
* Antimetabolites
* Corticosteroids
* JAK inhibitors


Chapter 4: Autoimmune Drug Manufacturer Profiles

This chapter provides analysis of nine top autoimmune drug makers’ portfolios. Company profiles include:

* Ranking within market
* Strengths analysis
* Growth areas analysis
* Key products breakdown